Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer

References

• Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8–29
   PubMed Web of Science ®Google Scholar
• Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60: 2035–41
   PubMed Web of Science ®Google Scholar
• Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984; 63: 825–32
   PubMed Web of Science ®Google Scholar
• Ayhan A, Tuncer R, Tuncer ZS, Yuce K, Kucukali T. Correlation between clinical and histopathologic risk factors and lymph node metastases in early endometrial cancer (a multivariate analysis of 183 cases). Int J Gynecol Cancer 1994; 4: 306–9
   PubMed Web of Science ®Google Scholar
• Fanning J, Piver MS. Serial CA 125 levels during chemotherapy for metastatic or recurrent endometrial cancer. Obstet Gynecol 1991; 77: 278–80
   PubMed Web of Science ®Google Scholar
• Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Jr, Knapp RC, Bast RC, Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984; 148: 1057–8
   PubMed Web of Science ®Google Scholar
• Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986; 155: 1097–102
   PubMed Web of Science ®Google Scholar
• Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 1994; 84: 12–6
   PubMed Web of Science ®Google Scholar
• Patsner B, Mann WJ, Cohen H, Loesch M. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol 1988; 158: 399–402
   PubMed Web of Science ®Google Scholar
• Scambia G, Gadducci A, Panici PB, Foti E, Ferdeghini M, Ferrandina G, et al. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol Oncol 1994; 54: 292–7
   PubMed Web of Science ®Google Scholar
• Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA12-5 levels in treating endometrial cancer. J Reprod Med 2005; 50: 585–90
   PubMed Web of Science ®Google Scholar
• Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005; 97: 560–6
   PubMedGoogle Scholar
• DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol 1985; 151: 1009–15
   PubMed Web of Science ®Google Scholar
• Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC, Jr. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 1990; 163: 1204–9
   PubMed Web of Science ®Google Scholar
• Takeshima N, Shimizu Y, Umezawa S, Hirai Y, Chen JT, Fujimoto I, et al. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol Oncol 1994; 54: 321–6
   PubMed Web of Science ®Google Scholar
• Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997; 90: 441–7
   PubMed Web of Science ®Google Scholar
• Yamazawa K, Hirashiki K, Usui H, Mitsuhashi A, Matsui H, Sekiya S. Discordance between serum level and tissue immunohistochemical staining of CA125 in endometrioid adenocarcinoma of the uterine corpus. Int J Gynecol Pathol 2005; 24: 254–9
   PubMed Web of Science ®Google Scholar
• National Statistical Office RoK. The Causes of Death Statistics (Death and Death rates). 2004.
   Google Scholar
• Peters-Engl C, Buxbaum P, Ogris E, Sevelda P, Medl M. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer. Anticancer Res 1998; 18: 4635–9
   PubMed Web of Science ®Google Scholar
• Koper NP, Massuger LF, Thomas CM, Kiemeney LA, Verbeek AL. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy. Anticancer Res 1998; 18: 1897–902
   PubMed Web of Science ®Google Scholar
• Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 2004; 95: 463–8
   PubMed Web of Science ®Google Scholar
• Santala M, Talvensaari-Mattila A, Kauppila A. Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res 2003; 23: 3097–103
   PubMed Web of Science ®Google Scholar
• Alagoz T, Buller RE, Berman M, Anderson B, Manetta A, DiSaia P. What is a normal CA125 level?. Gynecol Oncol 1994; 53: 93–7
   PubMed Web of Science ®Google Scholar